Lunit, a medical artificial intelligence (AI) company, used AI to analyze cancer tissue and identify clues that distinguish patients’ responses to immunotherapy. The findings showed that the location of immune cells within a tumor is more closely associated with treatment response than their number.

Lunit to Participate in SITC 2026

Lunit to Participate in SITC 2026

View original image

According to Lunit on Nov. 5, the company plans to present two collaborative studies using its AI biomarker platform, Lunit SCOPE, at the Society for Immunotherapy of Cancer (SITC 2026), taking place in Phoenix, U.S., from Nov. 4 to 8 (local time).


An analysis conducted with CellCarta of tissue samples from patients with muscle-invasive bladder cancer before and after immunotherapy found that patients who responded to treatment had greater immune cell infiltration, with cancer-attacking T cells located closer to the tumor. In patients who did not respond, most T cells had impaired function and were located far from the tumor.


With Labcorp, Lunit analyzed tissue samples from 339 patients with ovarian cancer. Among patients with homologous recombination deficiency (HRD), a defect in DNA damage repair, the density of proliferating cells was about 1.5 times that of patients without HRD. Their tumor mutational burden (TMB) was also twice as high. The score from an AI model that predicts HRD status based solely on tissue images showed a significant correlation with genomic test results.



“Reading complex relationships among cells all at once is an area where AI can excel,” said Lunit CEO Seo Beomseok. “We will further develop Lunit SCOPE into an essential platform for next-generation biomarker analysis.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing